Novavax (NVAX)
(Delayed Data from NSDQ)
$13.85 USD
-1.11 (-7.42%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $13.86 +0.01 (0.07%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NVAX 13.85 -1.11(-7.42%)
Will NVAX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NVAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVAX
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
NVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Bulls Look Optimistic About Novavax (NVAX): Should You Buy?
Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider
Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine
Other News for NVAX
Novavax call volume above normal and directionally bullish
Novavax’s Promising Outlook: Strong Market Positioning and Strategic Partnerships Fuel Buy Rating
Novavax price target lowered by $7 at Jefferies, here's why
COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today